Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Fluvoxamine for COVID-19: real-time meta analysis of 6 studies
Covid Analysis, January 18, 2022, DRAFT
https://c19fluvoxamine.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lenze (DB RCT) 93% 0.07 [0.00-1.28] progression 0/80 6/72 Improvement, RR [CI] Treatment Control Lenze (DB RCT) 82% 0.18 [0.02-1.50] hosp. 1/80 5/72 Seftel (QR) 84% 0.16 [0.01-3.29] death/ICU 0/77 2/48 Seftel (QR) 94% 0.06 [0.00-1.04] hosp. 0/77 6/48 Seftel (QR) 99% 0.01 [0.00-0.21] no recov. 0/77 29/48 Lenze (DB RCT) 7% 0.93 [0.42-2.06] hosp. 11/272 12/275 Reis (DB RCT) 30% 0.70 [0.37-1.26] death 17/741 25/756 Reis (DB RCT) 91% 0.09 [0.01-0.47] death 1/548 12/618 Reis (DB RCT) 22% 0.78 [0.46-1.28] ventilation 26/741 34/756 Reis (DB RCT) 22% 0.78 [0.61-1.03] hosp. 75/741 97/756 Reis (DB RCT) 32% 0.68 [0.52-0.88] hosp./ER 79/741 119/756 Reis (DB RCT) 31% 0.69 [0.53-0.90] hosp./ER 78/740 115/752 Reis (DB RCT) 66% 0.34 [0.21-0.54] hosp./ER 541 (n) 609 (n) Reis (DB RCT) -49% 1.49 [0.94-2.38] viral+ 167/207 163/221 Calusic (PSM) 42% 0.58 [0.36-0.94] death 30/51 39/51 Oskotsky (PSM) -58% 1.58 [0.42-5.93] death 2/11 19/165 Oskotsky (PSM) 26% 0.74 [0.55-0.99] death 48/481 956/7,215 fluvoxamine COVID-19 outcomes c19fluvoxamine.com Jan 18, 2022 Favors fluvoxamine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit